{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:23:55Z","timestamp":1786487035179,"version":"build-2736575974"},"reference-count":102,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Psoriasis vulgaris is the commonest presentation of psoriatic disease, but morphologic variants such as pustular psoriasis (PP) and a closely related disease, pityriasis rubra pilaris (PRP), have been known for a long time, have been associated with rheumatologic manifestations indistinguishable from psoriatic arthritis (PsA) that may go unrecognized, and often represent a therapeutic conundrum. There is recent evidence that underlying genetic and pathogenetic differences may provide the basis for newer therapeutic approaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>This narrative review highlights the clinical, genetic and pathogenetic characteristics of PP and PRP, their association with PsA and recent developments in their treatment, especially with biologic agents targeting IL-36 and other cytokines of pathogenic relevance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The clinical manifestations of PP and PRP are less well known to rheumatologists than those of psoriasis, and recent advances in our insight on their pathogenesis may eventually overcome the therapeutic difficulties faced by dermatologists and rheumatologists in the management of these diseases and their rheumatologic manifestations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000882","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T13:00:49Z","timestamp":1655211649000},"page":"225-234","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Beyond plaque psoriasis \u2013 pathogenesis and treatment of other psoriasis phenotypes"],"prefix":"10.1097","volume":"34","author":[{"given":"Helena","family":"Iznardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"R2-20250526","first-page":"97","article-title":"Current developments in the immunology of psoriasis","volume":"93","author":"Gr\u00e4n","year":"2020","journal-title":"Yale J Biol Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/archderm.1991.01680080075005","article-title":"Generalized pustular psoriasis. A review of 63 cases","volume":"127","author":"Zelickson","year":"1991","journal-title":"Arch Dermatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2340\/00015555766871","article-title":"Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background","volume":"76","author":"Ohkawara","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol"},{"key":"R8-20250526","first-page":"669","article-title":"Generalized pustular psoriasis (Zumbusch): a French epidemiological survey","volume":"16","author":"Augey","year":"2006","journal-title":"Eur J Dermatol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"761","DOI":"10.5021\/ad.2017.29.6.761","article-title":"Prevalence of Psoriasis in Korea: a population-based epidemiological study using the Korean National Health Insurance Database","volume":"29","author":"Lee","year":"2017","journal-title":"Ann Dermatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2133.1968.tb11947.x","article-title":"Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases","volume":"80","author":"Baker","year":"1968","journal-title":"Br J Dermatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","article-title":"Palmoplantar pustulosis: current understanding of disease definition and pathomechanism","volume":"98","author":"Murakami","year":"2020","journal-title":"J Dermatol Sci"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archderm.1934.01460100066006","article-title":"Recalcitrant pustular eruptions of the palms and soles","volume":"29","author":"Andrews","year":"1934","journal-title":"Arch Dermatol Syphilol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archderm.1935.01470060002001","article-title":"Pustular bacterids of the hands and feet","volume":"32","author":"Andrews","year":"1935","journal-title":"Arch Dermatol Syphilol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.1957.tb13266.x","article-title":"Intractable pustular eruptions of the hands and feet","volume":"69","author":"Everall","year":"1957","journal-title":"Br J Dermatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2133.1930.tb09380.x","article-title":"Acrodermatitis continua Vel Perstans (dermatitis Repens) and psoriasis pustulosa\u2217","volume":"42","author":"Barber","year":"1930","journal-title":"Br J Dermatol"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"e006450","DOI":"10.1136\/bmjopen-2014-006450","article-title":"Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database","volume":"5","author":"Kubota","year":"2015","journal-title":"BMJ Open"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.40.6.547","article-title":"Clinical features of 53 cases with pustulotic arthro-osteitis","volume":"40","author":"Sonozaki","year":"1981","journal-title":"Annof the Rheum Dis"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.semarthrit.2012.05.006","article-title":"The SAPHO syndrome","volume":"42","author":"Nguyen","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41423-020-0519-3","article-title":"Autoinflammatory psoriasis\u2019-genetics and biology of pustular psoriasis","volume":"18","author":"Uppala","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/nyas.13280","article-title":"The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases","volume":"1417","author":"Walsh","year":"2018","journal-title":"Ann NY Acad Sci"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.3390\/ijms20133318","article-title":"The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","volume":"20","author":"Madonna","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1189\/jlb.3RI1014-495R","article-title":"Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions","volume":"97","author":"Gabay","year":"2015","journal-title":"J Leukoc Biol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.4049\/jimmunol.1302574","article-title":"Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36\u03b3 induction in human epidermal keratinocytes","volume":"193","author":"Li","year":"2014","journal-title":"J Immunol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/biomedicines9121746","article-title":"Pustular psoriasis: from pathophysiology to treatment","volume":"9","author":"Genovese","year":"2021","journal-title":"Biomedicines"},{"key":"R27-20250526","first-page":"1207","article-title":"Treatment of pityriasis rubra pilaris with risankizumab in two cases","volume":"19","author":"Kromer","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaad.2021.06.008","article-title":"Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan","volume":"86","author":"Miyachi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/1346-8138.13306","article-title":"Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study","volume":"43","author":"Imafuku","year":"2016","journal-title":"J Dermatol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jdv.15287","article-title":"Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J)","volume":"33","author":"Okubo","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjd.14702","article-title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br J Dermatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/1346-8138.14294","article-title":"Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study","volume":"45","author":"Sano","year":"2018","journal-title":"J Dermatol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","article-title":"Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial","volume":"155","author":"Terui","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/1346-8138.16132","article-title":"Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5\u200ayears in a randomized phase 3 study","volume":"48","author":"Okubo","year":"2021","journal-title":"J Dermatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamadermatol.2017.5937","article-title":"Efficacy and safety of guselkumab, an anti\u2013interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial","volume":"154","author":"Terui","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jdv.12272","article-title":"Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial","volume":"28","author":"Bissonnette","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","article-title":"Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study","volume":"80","author":"Mrowietz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2020.06.038","article-title":"Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: extension of the 2PRECISE study","volume":"84","author":"Mrowietz","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjd.13012","article-title":"Partial clinical response to anakinra in severe palmoplantar pustular psoriasis","volume":"171","author":"Tauber","year":"2014","journal-title":"Br J Dermatol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/14740338.2020.1785427","article-title":"Biologics in the treatment of pustular psoriasis","volume":"19","author":"Wang","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjd.14685","article-title":"Successful response in a case of severe pustular psoriasis after interleukin-1\u03b2 inhibition","volume":"176","author":"Skendros","year":"2017","journal-title":"Br J Dermatol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/ced.12759","article-title":"Palmoplantar pustular psoriasis unresponsive to the interleukin-1\u03b2 antagonist canakinumab","volume":"41","author":"Mansouri","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br J Dermatol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N Engl J Med"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","article-title":"Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a Phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study","volume":"11","author":"Mrowietz","year":"2021","journal-title":"Dermatol Ther"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/11530070-000000000-00000","article-title":"Pityriasis rubra pilaris: a review of diagnosis and treatment","volume":"11","author":"Klein","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/jdv.14761","article-title":"Pityriasis rubra pilaris: algorithms for diagnosis and treatment","volume":"32","author":"Roenneberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2230.1980.tb01676.x","article-title":"Pityriasis rubra pilaris","volume":"5","author":"Griffiths","year":"1980","journal-title":"Clin Exp Dermatol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0190-9622(08)80734-7","article-title":"Pityriasis rubra pilaris in a patient with human immunodeficiency virus infection","volume":"27","author":"Auffret","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000251995","article-title":"Pityriasis rubra pilaris with muscle and joint involvement","volume":"146","author":"Aguilar","year":"1973","journal-title":"Dermatologica"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2214\/ajr.149.5.1082","article-title":"Acro-osteolysis secondary to pityriasis rubra pilaris","volume":"149","author":"Duke","year":"1987","journal-title":"AJR Am J Roentgenol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1365-2133.1996.tb07968.x","article-title":"Arthropathic pityriasis rubra pilaris","volume":"134","author":"Fiallo","year":"1996","journal-title":"Br J Dermatol"},{"key":"R54-20250526","first-page":"318","article-title":"Pityriasis rubra pilaris and a seronegative polyarthritis","volume":"137","author":"Lister","year":"1997","journal-title":"Br J Dermatol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/1529-0131(199909)42:9<1998::AID-ANR28>3.0.CO;2-D","article-title":"The relationship between pityriasis rubra pilaris and inflammatory arthritis: case report and response of the arthritis to antitumor necrosis factor immunotherapy","volume":"42","author":"Conaghan","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1525-1470.2002.00004.x","article-title":"Atypical pityriasis rubra pilaris associated with arthropathy and osteoporosis: a case report with 15-year follow-up","volume":"19","author":"Behr","year":"2002","journal-title":"Pediatr Dermatol"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000065842","article-title":"Pityriasis rubra pilaris in association with polyarthritis","volume":"205","author":"Nakafusa","year":"2002","journal-title":"Dermatology"},{"key":"R58-20250526","first-page":"57","article-title":"A review of pityriasis rubra pilaris and rheumatologic associations","volume":"11","author":"Chan","year":"2004","journal-title":"Clin Dev Immunol"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2177\/jsci.27.407","article-title":"A case of pityriasis rubra pilaris associated with rapidly progressive finger joint destruction","volume":"27","author":"Ohashi","year":"2004","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1468-3083.2007.02502.x","article-title":"A case of pityriasis rubra pilaris associated with sacroileitis and autoimmune thyroiditis","volume":"22","author":"G\u00fcl","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"bcr1220092565","DOI":"10.1136\/bcr.12.2009.2565","article-title":"Arthritis associated with pityriasis rubra pilaris","volume":"2010","author":"Liu","year":"2010","journal-title":"BMJ Case Rep"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2012.09.018","article-title":"Pityriasis rubra pilaris with polyarthritis treated with adalimumab","volume":"68","author":"Chiu","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1067\/mjd.2000.102648","article-title":"An unusual presentation of dermatomyositis: the type Wong variant revisited","volume":"43","author":"Lupton","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2133.1997.6721620.x","article-title":"Dermatomyositis with a pityriasis rubra pilaris-like eruption: a little-known distinctive cutaneous manifestation of dermatomyositis","volume":"136","author":"Requena","year":"1997","journal-title":"Br J Dermatol"},{"key":"R65-20250526","first-page":"626","article-title":"Pityriasis rubra pilaris and celiac sprue with malabsorption","volume":"25","author":"Randle","year":"1980","journal-title":"Cutis"},{"key":"R66-20250526","first-page":"6","article-title":"Systemic sclerosis in a patient with pityriasis rubra pilaris","volume":"6","author":"Frikha","year":"2010","journal-title":"Pan Afr Med J"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4314\/pamj.v10i0.72213","article-title":"Association of pityriasis rubra pilaris and myasthenia","volume":"10","author":"Agharbi","year":"2011","journal-title":"Pan Afr Med J"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2016.0091","article-title":"Epidemiologic, clinicopathologic, diagnostic and management challenges of Pityriasis Rubra Pilaris","volume":"152","author":"Ross","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","article-title":"Familial pityriasis rubra pilaris is caused by mutations in CARD14","volume":"91","author":"Fuchs-Telem","year":"2012","journal-title":"Am J Hum Genet"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamadermatol.2016.3601","article-title":"Pityriasis rubra pilaris type V as an autoinflammatory disease by CARD14 mutations","volume":"153","author":"Takeichi","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/pde.14779","article-title":"CARD14-associated papulosquamous eruption (CAPE) in pediatric patients: three additional cases and review of the literature","volume":"38","author":"Frare","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdermsci.2018.01.012","article-title":"Autoinflammatory keratinization diseases: an emerging concept encompassing various inflammatory keratinization disorders of the skin","volume":"90","author":"Akiyama","year":"2018","journal-title":"J Dermatol Sci"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23-Helper T Cell 17 axis as a treatment target for pityriasis rubra pilaris","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R74-20250526","doi-asserted-by":"crossref","first-page":"e14403","DOI":"10.1111\/dth.14403","article-title":"Successful treatment of pityriasis rubra pilaris with guselkumab: Serum CCL20 as a potential marker for the disease activity","volume":"33","author":"Nagai","year":"2020","journal-title":"Dermatol Ther"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1111\/j.1468-3083.2012.04456.x","article-title":"A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists","volume":"27","author":"Petrof","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2133.2010.09855.x","article-title":"Treatment of pityriasis rubra pilaris with ustekinumab","volume":"163","author":"Wohlrab","year":"2010","journal-title":"Br J Dermatol"},{"key":"R77-20250526","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3315\/jdcr.2013.1127","article-title":"Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris","volume":"7","author":"Di Stefani","year":"2013","journal-title":"J Dermatol Case Rep"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/1346-8138.12927","article-title":"Successful response of refractory type I adult-onset pityriasis rubra pilaris with ustekinumab and acitretin combination therapy","volume":"42","author":"Byekova","year":"2015","journal-title":"J Dermatol"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000381011","article-title":"Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris","volume":"7","author":"Chowdhary","year":"2015","journal-title":"Case Rep Dermatol"},{"key":"R80-20250526","first-page":"630","article-title":"Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy","volume":"20","author":"Ruiz Villaverde","year":"2010","journal-title":"Eur J Dermatol"},{"key":"R81-20250526","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1111\/jdv.14009","article-title":"Efficacy of ustekinumab after failure of infliximab CT-P13 in a HLA-Cw6-positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (RCM) and optical coherence tomography (OCT)","volume":"31","author":"Paganelli","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R82-20250526","doi-asserted-by":"crossref","first-page":"e14223","DOI":"10.1111\/dth.14223","article-title":"Erythrodermic pityriasis rubra pilaris treatment: two case reports and literature review","volume":"33","author":"Camela","year":"2020","journal-title":"Dermatol Ther"},{"key":"R83-20250526","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjd.12952","article-title":"Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14","volume":"171","author":"Eytan","year":"2014","journal-title":"Br J Dermatol"},{"key":"R84-20250526","doi-asserted-by":"crossref","first-page":"e14097","DOI":"10.1111\/dth.14097","article-title":"Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: a case report and literature review","volume":"33","author":"Liang","year":"2020","journal-title":"Dermatol Ther"},{"key":"R85-20250526","doi-asserted-by":"crossref","first-page":"e13644","DOI":"10.1111\/dth.13644","article-title":"Successful treatment of resistant pityriasis rubra pilaris with ixekizumab","volume":"33","author":"Penalba-Torres","year":"2020","journal-title":"Dermatol Ther"},{"key":"R86-20250526","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000488902","article-title":"Successful treatment of pityriasis rubra pilaris with ixekizumab","volume":"10","author":"Hanfstingl","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"R87-20250526","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00105-020-04575-6","article-title":"Pityriasis rubra pilaris: Successful treatment with ixekizumab","volume":"71","author":"Kohn","year":"2020","journal-title":"Hautarzt"},{"key":"R88-20250526","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jdcr.2018.05.006","article-title":"Successful treatment of type I pityriasis rubra pilaris with ixekizumab","volume":"4","author":"Heibel","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R89-20250526","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ajd.13614","article-title":"A case of treatment-resistant pityriasis rubra pilaris responsive to secukinumab","volume":"62","author":"Simpson","year":"2021","journal-title":"Australas J Dermatol"},{"key":"R90-20250526","first-page":"501","article-title":"Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris","volume":"156","author":"Papini","year":"2021","journal-title":"Ital J Dermatol Venerol"},{"key":"R91-20250526","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/bjd.18263","article-title":"Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab","volume":"181","author":"Cole","year":"2019","journal-title":"Br J Dermatol"},{"key":"R92-20250526","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamadermatol.2016.3885","article-title":"Successful treatment of refractory pityriasis rubra pilaris with secukinumab","volume":"152","author":"Schuster","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R93-20250526","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jdcr.2016.09.006","article-title":"Successful treatment of type II pityriasis rubra pilaris with secukinumab","volume":"2","author":"Gauci","year":"2016","journal-title":"JAAD Case Rep"},{"key":"R94-20250526","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jdcr.2018.02.007","article-title":"Secukinumab in pityriasis rubra pilaris: a case series demonstrating variable response and the need for minimal clinical datasets","volume":"4","author":"Wain","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R95-20250526","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jaad.2018.02.063","article-title":"Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: a review","volume":"79","author":"Maloney","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R96-20250526","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamadermatol.2020.0932","article-title":"Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial","volume":"156","author":"Haynes","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R97-20250526","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/ijd.14857","article-title":"Familial pityriasis rubra pilaris successfully treated with brodalumab","volume":"59","author":"De Felice","year":"2020","journal-title":"Int J Dermatol"},{"key":"R98-20250526","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/ijd.15219","article-title":"Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab","volume":"60","author":"Amat-Samaranch","year":"2021","journal-title":"Int J Dermatol"},{"key":"R99-20250526","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamadermatol.2019.2774","article-title":"Treatment of pityriasis rubra pilaris with guselkumab","volume":"155","author":"Pilz","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R100-20250526","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1111\/bjd.19681","article-title":"Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab","volume":"184","author":"Ricar","year":"2021","journal-title":"Br J Dermatol"},{"key":"R101-20250526","doi-asserted-by":"crossref","first-page":"e15112","DOI":"10.1111\/dth.15112","article-title":"Is risankizumab effective in the treatment of pityriasis rubra pilaris?","volume":"34","author":"Balestri","year":"2021","journal-title":"Dermatol Ther"},{"key":"R102-20250526","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ajd.13753","article-title":"Successful treatment of pityriasis rubra pilaris with tildrakizumab","volume":"63","author":"Zagarella","year":"2022","journal-title":"Australas J Dermatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:17:13Z","timestamp":1748294233000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000882","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]}}}